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A B S T R A C T
Elevated intraocular pressure (IOP) is a major risk factor for the development of primary open-angle glaucoma
(POAG). This is from an increased aqueous humour (AH) outﬂow resistance through the trabecular meshwork
(TM). The pathogenic mechanisms leading to the increase in TM outﬂow resistance are poorly understood but
are thought to be from a dysregulation of the TM extracellular matrix (ECM) environment. ECM modiﬁcation
and turnover are crucial in regulating the resistance to aqueous outﬂow. ECM turnover is inﬂuenced by a
complex interplay of growth factors such as transforming growth factors (TGFβ) family and matrix metallo-
proteinases (MMPs). Elevated TGFβ2 levels result in an increase in ECM deposition such as ﬁbronectin leading to
increased resistance. Fibronectin is a major component of TM ECM and plays a key role in its maintenance.
Thrombospondins (TSP)-1 and−2 are important regulators of the ECM environment. TSP-1 has been implicated
in the pathogenesis of POAG through activation of TGFβ2 within the TM. TSP-2 does not contain the catalytic
domain to activate latent TGFβ, but is able to mediate the activities of MMP 2 and 9, thereby inﬂuencing ECM
turnover. TSP-2 knock out mice show lower IOP levels compared to their wild type counterparts, suggesting the
involvement of TSP-2 in the pathogenesis of POAG but its role in the pathogenesis of POAG remains unclear. The
purpose of this study was to investigate the role of TSP-2 in trabecular meshwork ECM regulation and hence the
pathogenesis of POAG.
TSP-1 and TSP-2 expressions in immortalised glaucomatous TM cells (GTM3) and primary human non-
glaucomatous (NTM) and glaucomatous cells (GTM) were determined by immunocytochemistry, immuno-blot
analysis and qPCR following treatment with TGFβ2 and Dexamethasone. The level of ECM protein ﬁbronectin
was determined in TM cells using immuno-blot analysis following treatment with TSP-1 or -2.
TM cells secrete TSP-1 and -2 under basal conditions at the protein level and TSP-2 mRNA and protein levels
were increased in response to TGFβ2 three days post treatment. Exogenous treatment with TSP-2 up-regulated
the expression of ﬁbronectin protein in GTM3 cells, primary NTM and GTM cells. TSP-1 did not aﬀect ﬁbronectin
protein levels in GTM3 cells. This suggests that the role of TSP-2 might be distinct from that of TSP-1 in the
regulation of the TM cell ECM environment. TSP-2 may be involved in the pathogenesis of POAG and contribute
to increased IOP levels by increasing the deposition of ﬁbronectin within the ECM in response to TGFβ2.
1. Introduction
The trabecular meshwork (TM) is the major site of aqueous humour
(AH) outﬂow in the eye under normal physiological conditions (Bill and
Phillips, 1971) and the principal regulator of intraocular pressure (IOP)
levels (Llobet et al., 2003). Elevated IOP is a major risk factor in the
development and progression of primary open angle glaucoma (POAG)
and leads to damage at the optic nerve head with consequent visual
ﬁeld loss. There is increased AH outﬂow resistance through an impaired
outﬂow drainage system in the TM. The pathogenic mechanisms of
increased outﬂow resistance in glaucomatous TM are poorly under-
stood, but are thought to include an increased deposition of
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extracellular matrix (ECM) components (Faralli et al., 2009;
Lutjendrecoll et al., 1989; Tamm and Fuchshofer, 2007), loss of cells
(Alvarado et al., 1984) and alterations in the cytoskeletal organisation
in TM cells (O'reilly et al., 2011; Tan et al., 2006).
The TM ECM plays a critical role in regulating the AH outﬂow re-
sistance (Haddadin et al., 2012; Tamm and Fuchshofer, 2007), whereby
the amount and quality of ECM material is inﬂuenced by the dynamic
re-structuring and turnover of proteins (Faralli et al., 2009; Tamm and
Fuchshofer, 2007). Histological and morphological studies have shown
an increase in ECM “plaque material” within the TM of glaucomatous
eyes (Lutjendrecoll et al., 1989), which correlates with damage in the
optic nerve (Faralli et al., 2009; Flugel-Koch et al., 2004; Maatta et al.,
2005; Tamm and Fuchshofer, 2007; Wordinger et al., 2007). ECM
components collagen type IV, collagen type VI, laminin and ﬁbronectin
are found in higher amounts in the TM of eyes with POAG (Faralli et al.,
2009; Flugel-Koch et al., 2004). ECM modiﬁcation and turnover are
crucial in regulating the resistance to aqueous outﬂow. A shift in the
balance of ECM formation and degradation may increase ECM deposi-
tion and restrict the outﬂow of AH across the TM, providing a physical
resistance aﬀecting the contractile properties of the TM (Faralli et al.,
2009). The precise mechanisms of ECM turnover in the TM in POAG
remain unclear.
ECM turnover is inﬂuenced by a complex interplay of growth factors
such as transforming growth factors (TGFβ) family and matrix me-
talloproteinases (MMPs). TGFβ1 and β2 play an important role in the
pathogenesis of POAG, where increased levels of TGFβ2 are present in
the AH and TM of glaucomatous eyes (Flugel-Koch et al., 2004;
Wordinger et al., 2007). Elevated TGFβ2 levels result in an increase in
ECM deposition (such as ﬁbronectin, collagen I, IV and VI) and cross-
linking that impedes ECM degradation in cultured TM cells (Tamm and
Fuchshofer, 2007) and also within organ culture models (Fleenor et al.,
2006, Welge-Lussen and Lutjen-Drecoll, 2000). In vitro studies have
shown that the continuous perfusion of human anterior segments with
TGFβ2 generates a time dependent increase in IOP over 24 hours (h)
(Fleenor et al., 2006). Likewise, the levels of tissue inhibitor of me-
talloproteinases (TIMP-2) are signiﬁcantly increased over MMP-2 levels
in POAG (Maatta et al., 2005), suggesting a reduction in ECM turnover
in the TM. Perfusion of anterior segments with MMP's leads to a re-
versible increase in outﬂow facility (Bradley et al., 1998; Fuchshofer
and Tamm, 2012).
TGFβ2 is secreted as an inactive cytokine that needs to be activated
before it can bind to its receptors. Thrombospondin (TSP)-1, a secreted
ECM protein, is a potent activator of latent TGFβ in vivo and in vitro
(Crawford et al., 1998; Murphy-Ullrich and Poczatek, 2000;
Schultzcherry et al., 1995) and is implicated in the pathogenesis of
POAG (Flugel-Koch et al., 2004). TSPs belong to a family of ma-
tricellular proteins, of which the TSPs are categorized according to their
trimeric (TSP-1 and -2) or pentameric (TSP 3–5) structure (Adams and
Lawler, 2011). TSP-1 and-2 comprises the subgroup A TSPs and mod-
ulate cell-matrix interactions and cell behaviour. TSP-1 and -2 inﬂuence
cell function by interacting with cell surface receptors, ECM, growth
factors and proteases (Bornstein and Sage, 2002). TSP-1 and TSP-2
share some sequence homology, but diﬀer in some speciﬁc regions
(Bornstein, 1992). This is reﬂected by their diﬀerential expression
within tissues where they potentially carry out speciﬁc functions. TSP-1
can activate TGFβ and bind to a number of ECM proteins such as col-
lagens I–V, laminin and ﬁbronectin (Murphy-Ullrich and Poczatek,
2000; Tan and Lawler, 2009). In contrast, TSP-2 does not contain the
catalytic domain to activate latent TGFβ, but is able to mediate the
activities of MMP2 and -9, inﬂuencing ECM turnover (Hiscott et al.,
2006; Rhee et al., 2009). Moreover, TSP-2 is reported to inhibit TSP-1
activation of latent TGFβ by competitively binding with latent TGFβ
(Schultzcherry et al., 1995).
TSP-1 and -2 are localised in normal TM, expressing diﬀerent lo-
calisation patterns (Hiscott et al., 2006). TSP-2 is pre-dominantly ex-
pressed within the uveal meshwork, whilst TSP-1 is expressed in the
juxta-canalicular (JCT) meshwork of the TM tissue. TSP-1 expression is
up-regulated in glaucomatous eyes (Flugel-Koch et al., 2004) and TSP-1
mRNA has been detected in both fresh and cultured TM cells and is up-
regulated by both TGFβ1 (Tamm et al., 2004) and dexamethasone
(DEX) in glaucomatous TM (Flugel-Koch et al., 2004). The role of TSP-2
in the TM is less well deﬁned. TSP-2 knock out mice show lower IOP
levels, compared to their wild type counterparts, suggesting the in-
volvement of TSP-2 in the pathogenesis of POAG (Haddadin et al.,
2012). It is possible that TSP-2 plays a role in glaucoma via its reg-
ulation of MMP activity and, hence, ECM turnover.
The precise molecular mechanisms involving ECM turnover remain
unclear and elucidating the mechanisms of ECM regulation may pro-
vide future targets for regulation of ECM in the TM. TSP-1 and -2 can
inﬂuence ECM alterations and are well placed in contributing to the
pathogenesis of glaucoma. TSP-1 has been shown to be involved in the
pathogenesis of POAG through activation of TGFβ2 within the TM. We
hypothesise that TSP-2 may be involved in the pathogenesis of POAG
through the regulation of ECM turnover via the TGFβ2 signalling
pathway. TGFβ2 has been implicated in the pathogenesis of POAG,
while DEX is widely used as an inducer of glaucomatous changes in TM
cells both by ourselves and others (Clark et al., 2005; Clark et al., 1995;
Clark et al., 2013, O'reilly et al., 2011). Fibronectin ﬁbrils are a major
component of the ECM and play a key role in the maintenance of ECM
in the TM under both normal and glaucomatous conditions (Filla et al.,
2017). We investigated the eﬀects of TGFβ2 and DEX upon TSP-2 ex-
pression and the eﬀect of TSP-1 and -2 upon ﬁbronectin expression in
normal and glaucomatous primary and a immortalised glaucomatous
cell line.
2. Materials and methods
2.1. TM cell culture
Human transformed glaucomatous TM cells (GTM3) were obtained
from Alcon Research Laboratories (Fort Worth, Texas, USA). Human
primary TM cells (glaucomatous (GTM) and non-glaucomatous (NTM))
were either from either Alcon Research Laboratories (Fort Worth,
Texas, USA) or derived from explants of TM tissue from corneal-scleral
rims obtained from St Paul's Eye Unit, Royal Liverpool University
Hospital; UK and Liverpool Research Eye Bank; UK, following pre-
viously described methods (Keller et al., 2018). All tissue adhered to the
tenets of the Declaration of Helsinki and local ethics board ((01/066).
TM cells were grown in Dulbecco's modiﬁed Eagle's medium (DMEM),
low glucose supplemented with 2mML–glutamine, 50 U/ml penicillin
G, 50 μg/ml streptomycin, 2.5 μg/ml amphotericin B (Sigma, St Louis,
MO) and 10% v/v heat-inactivated fetal bovine serum (FBS; Biosera,
East Sussex, UK). All cells were grown at 37 °C in controlled humidity
and 5% CO2 atmosphere. GTM3 have been characterised in other stu-
dies (O'reilly et al., 2011); primary TM cells were characterised with a
panel of markers (chitinase-3 like-1 (1 μg/ml, Abcam, UK), tissue in-
hibitor of metalloproteinase −3 (1 μg/ml, Abcam, UK), and myocillin
(1 μg/ml, R&D Systems, UK) (following 100 nM DEX treatment) Abcam,
UK), as previously described (Keller et al., 2018; Stamer and Clark,
2017; Ding et al., 2014). All experiments using primary TM cells were
used between passages 3-4. Primary cells were isolated from donors
65–80 years of age.
2.2. TM cell treatments and time course experiments
Human primary TM and immortalised cells (GTM3) cells were
grown to conﬂuence and media containing 10% (v/v) FBS replaced
every three days until 70–80% conﬂuence was achieved. TM cells were
serum starved for approximately 18 h prior to drug treatments in serum
free medium. Recombinant human TGFβ2 (R&D Systems, UK) was
made up in 4mM HCL/bovine serum albumin (BSA). Recombinant
human TSP-1 and TSP-2 proteins (R&D Systems, UK) were reconstituted
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in phosphate buﬀered saline (PBS). DEX (Sigma UK) was reconstituted
to a working solution of 100 nM in growth media. For TSP-2 and -1
expression experiments, primary TM cells were incubated with fresh
serum free medium containing 2 ng/ml recombinant human TGFβ2
protein (Fuchshofer et al., 2009; Kasetti et al., 2018; Flugel-Koch et al.,
2004) or 100 nM DEX for three days (Jain et al., 2013; Kasetti et al.,
2017). To investigate the expression of ﬁbronectin, TM cells were
treated with 2 μg/ml TSP-2 or TSP-1 recombinant human proteins for
three days (Armstrong et al., 2003). Control TM cells for all experiments
were grown as described above and replaced with fresh serum free
medium at time of treatment.
2.3. Protein extraction and immuno-blot analysis
Total protein cell lysates were prepared from conﬂuent normal and
glaucomatous TM cells three days following the appropriate drug
treatment. Cultured cells were lysed in ice cold RIPA lysis buﬀer
(50mM Tris-HCL pH 7.4, 50mM NaCl, 2 mM EDTA, 0.1% (v/v) SDS),
with cOmplete™ Protease Inhibitor Cocktail tablets (Roche, UK) for
5min and cell lysates harvested by scraping. Prior to sample loading,
lysates were loaded with 4X Laemmli sample buﬀer (Biorad, UK) and
heated to 95 °C for 5min. Proteins were resolved by SDS-PAGE on a
7.5% (w/v) gel under reducing and denaturing conditions before
transfer to nitrocellulose membrane at 80 V for 2 h. Primary antibody
solutions used were prepared in 5% (w/v) BSA dissolved in 0.1% (v/v)
PBS Tween 20. Antibody concentrations were: anti-TSP-2 goat poly-
clonal (2 μg/ml, R&D Systems. UK), anti-TSP-1 goat polyclonal (2 μg/
ml, R&D Systems, UK), anti-α tubulin mouse (1.2 μg/ml, Sigma, UK)
and anti-ﬁbronectin rabbit (1.2 μg/ml, Sigma, UK). Blots were re-
probed with anti-α tubulin antibody to conﬁrm equal loading of sam-
ples. Immuno-complexes were detected with horseradish peroxidase-
conjugated secondary antibody (Sigma-Aldrich) by a chemi-lumines-
cent method (SuperSignal®West Pico Chemiluminescent Substrate,
ThermoScientiﬁc, UK), using a BioRad Geldoc system. Relative in-
tensities of the protein bands (180 kDa band for TSP-2 and -1 (Streit
et al., 1999) and 250 kDa band for ﬁbronectin) were obtained by den-
sitometry analysis using Biorad Image Lab analysis software (version
5.0 build 18) and normalised to endogenous α-tubulin or total protein
using Ponceau staining.
2.4. Immunocytochemistry
TM cells were seeded into glass four well Lab-Tek Chamber Slides at
5000 cells/cm2 (Nunc, Rochester, NY, USA) and grown to pre con-
ﬂuence and serum starved before drug treatments were performed as
described in 2.2. Media was removed following treatment at indicated
times and cells were washed in PBS. Cells were ﬁxed with 4% (v/v)
Neutral Buﬀered Formalin in PBS for 10min followed by 3×5min
washes. Following permeabilization with 0.3% (w/v) Triton X-100 in
PBS for 5min, followed by a 5min PBS wash, cells were incubated in
blocking buﬀer (5% (w/v) normal rabbit or goat serum (Sigma, UK) in
PBS) for 60min at 37 °C before incubating with primary antibody di-
luted in antibody dilution buﬀer (1% (w/v) BSA in PBS) overnight at
4 °C. Cells were washed for 5min in PBS before addition of diluted
ﬂuorochrome-conjugated secondary antibodies (Invitrogen, UK) for
60min, followed by 3×5min washes in PBS (0.05% v/v Tween).
Nuclei were stained using propidium iodide (PI) 1 μg/ml or DAPI 1 μg/
ml (Invitrogen, UK). Slides were mounted with Fluorescence Mounting
Medium (Dako, Cambridgeshire, UK) and examined using a Zeiss LSM
510 confocal microscope for TSP-2 expression or a Nikon Eclipse Ti-E
cell microscope for wideﬁeld ﬂuorescence imaging.
2.5. RNA isolation and real-time quantitative PCR
Total RNA was isolated from TM cells, as described by the manu-
facturer (RNeasyKit, Qiagen Ltd. West Sussex, UK) with on-column
DNase I treatment for removal of genomic DNA. RNA concentration and
purity were assessed by spectrophotometry. Total RNA was reverse
transcribed and ﬁrst-strand cDNA was synthesized from 1 μg RNA using
SuperscriptII Reverse Transcriptase (Invitrogen, UK). Primers for TSP-1
and-2 were designed using Primer3web version 4.1.0 software and were
designed to span exon-exon junctions. Primer sequences used were TSP-
2 Forward GGGTGATATTTGTAAAGATGAT, TSP-2 Reverse GAAGTTC
CTGAAGTCTGT, TSP-1 Forward GGACTCGCTGTAGGTTATGATG, TSP-
1 Reverse CGGCTGCTGGACTGGTAG, GAPDH Forward AACAGCCTCA
AGATCATCAG, GAPDH Reverse TGAGTCCTTCCACGATACC.
Real-time qPCR was performed using LightCycler 480 Sybr Green 1
Master Kit (Roche, West Sussex, UK) as described by the manufacturer.
The PCR conditions were 1 pre incubation cycle of 95 °C for 5min,
followed by 40 ampliﬁcation cycles of 95 °C for 10 s, 60 °C for 10 s,
72 °C for 5 s. Incorporating 1 cycle of Melting curve of 95 °C for 5 s,
65 °C for 1min and 97 °C continuous step. Cooling was at 40 °C 1 cycle
for 10 s. Ampliﬁcations were performed in triplicate. Data were nor-
malised to GAPDH housekeeping gene and expressed as relative fold
changes in mRNA expression between control and experimental treat-
ment groups, determined using the 2−ΔΔCT method.
2.6. Statistical analysis
Data were analysed using Microsoft Excel and statistical analysis
performed using Minitab ® 17.1.0. Experiments were performed in tri-
plicate, with 3 independent experiments for TM cell lines. For experi-
ments using primary NTM and GTM cells 6 donors and 3 donors were
used, respectively unless stated otherwize. Comparisons between mul-
tiple groups were made using a one-way ANOVA, post hoc Tukey's HSD
analysis. Diﬀerences were considered statistically signiﬁcant at
p < 0.05.
3. Results
3.1. Expression and localisation of TSP-2 in trabecular meshwork cells
Expression of TSP-2 was investigated in GTM3 cell line, primary
NTM and GTM cells. It was observed that TSP-2 was localised
throughout the cytoplasm in GTM3 cells in a diﬀuse pattern (Fig. 1 A),
with punctate peri-nuclear staining following immunocytochemistry
and imaged by confocal microscopy ( identiﬁed by the arrow heads
Fig. 1 A (i, iv and v)). The cellular localisation of TSP-2 in primary
human NTM cells was observed as areas of punctate staining localised
to the cell cytoplasm (Fig. 1 B (i-iv)) and also within areas of ECM
around TM cells (identiﬁed by the arrow head in Fig. 1 B (iii).
TSP-2 protein expression was also further conﬁrmed in both pri-
mary NTM and GTM cells using immuno-blotting technique. TSP-2 ran
as a ~180 kDa protein band (Fig. 1 C (i)) (n= 3 donors for NTM and
n=3 donors for GTM). Densitometry analysis showed that there was a
signiﬁcant increase of TSP-2 expression of 1.9 fold in the primary GTM
cells relative to the primary NTM cells (Fig. 1 C (ii)).
3.2. TGFβ2 increases the expression of protein and mRNA levels of TSP-2 in
TM cells
TSP-2 and -1 protein expression levels were investigated in response
to TGFβ2 and DEX treatment in TM cells. TSP-1 and -2 protein ex-
pression levels from whole cell protein lysates of GTM3 cell line cells
were detected via immuo-blot analysis. TSP-1 protein levels served as a
positive control for positive TGFβ2 treatment upon TM cells. All TM
cells were treated with either 2 ng/ml TGFβ2 or 100 nM DEX for three
days and untreated cells were used as controls.
In the GTM3 cell line, immuno-blots revealed TSP-2 expression le-
vels increased approximately 1.6 fold in response to TGFβ2 treatment,
compared to untreated GTM3 cells (Fig. 2 A (i) and B (i)). TSP-1 protein
expression increased in response to TGFβ2, showing approximately a
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2.8 fold increase in TSP-1 expression levels, compared to untreated cells
(Fig. 2 A (ii) and B (ii)). DEX treatment did not signiﬁcantly increase
levels of TSP-1 and -2 (Fig. 2 A (i and ii) and B (i and ii)).
The mRNA levels of TSP-2 and TSP-1 were investigated in GTM3
cells following treatment with either 2 ng/ml TGFβ2 or 100 nM DEX for
three days. There was an approximately 4.9 fold increase in the ex-
pression of TSP-2 mRNA following treatment with TGFβ2 (Fig. 2 C (i))
for GTM3 cells, compared to control untreated cells. There was no
signiﬁcant increase in the expression of TSP-2 mRNA in GTM3 cells
(Fig. 2 C (i)) following treatment with 100 nM DEX for 3 days. TSP-1
mRNA expression increased 3.1 fold in the GTM3 cells with TGFβ2
treatment compared to control untreated cells (Fig. 2 C (ii)). No sig-
niﬁcant diﬀerence in TSP-1 mRNA expression was observed with DEX
treatment in the GTM3 cell line (Fig. 2 C (ii)).
In primary NTM cells TGFβ2 treatment increased TSP-2 protein
expression with approximately a 2.5 fold increase compared to un-
treated controls (Fig. 3 A (i) and B (i)). No signiﬁcant diﬀerence was
observed in the expression of TSP-2 in response to DEX in the primary
NTM cells (Fig. 3 A (i) and B (i)). Primary GTM cells showed approxi-
mately 1.7 fold increase in TSP-2 protein expression with both TGFβ2
and DEX treatments compared to untreated control cells (Fig. 3 A (ii)
and B (ii)).
Primary NTM cells showed a signiﬁcant increase in TSP-1 expres-
sion of approximately a 2 fold increase compared to untreated controls
(Fig. 3 A (iii) and B (iii)). No signiﬁcant diﬀerence was observed in TSP-
1 protein expression levels with DEX treatment in NTM cells (Fig. 3 A
(iii) and B (iii)). There was a distinct band for TSP-2 and TSP-1 at ap-
proximately 70 kDa that also showed an increase in response to TGFβ2
in both primary GTM and NTM cells (Fig. 3 A).
No signiﬁcant diﬀerence was observed in the mRNA expression of
TSP-2 in primary NTM or GTM cells with TGFβ2 or DEX treatment
(Fig. 3 C (i and ii)). TSP-1 mRNA expression was increased signiﬁcantly
in NTM cells with a 11.7 fold increase compared to untreated controls,
whilst DEX treatment showed no signiﬁcant diﬀerence (Figure C (iii)).
Fig. 1. TSP-2 localisation and expression in human TM cells. Immunocytochemistry of TSP-2 in GTM3 cultured cells. (A) (i) Merged image of GTM3 cells
expressing TSP-2 (green channel) and nuclei stained with PI (blue channel) Scale bar 50 μm. (A) (ii) represents TSP-2 staining and A (iii) represents PI stained cells.
Scale bar 50 μm. (A) (iv) Represents dual ﬂuorescence TSP-2 (green channel) and nuclei stained with PI (blue channel). (A) (v) TSP-2 staining single black and white
channel. Arrow heads indicate TSP-2 localisation. Scale bar 25 μm. (B) (i-iv) TSP-2 expression (green) and DAPI staining (blue) in primary NTM cells under basal
conditions from three donors. Arrow heads indicates regions of TSP-2 matrix expression (iii) and perinuclear staining (iv). Scale bar represents 100 μm. (C) Immuno-
blot analysis of TSP-2 protein expression in primary human TM cell lines under basal conditions. Cells were grown to conﬂuence and whole cell lysates were
separated by SDS PAGE, followed by immuno-blot analysis and probed for TSP-2 protein. (C) (i) TSP-2 expression in primary NTM (n=3) and GTM (n=3) cells as
180 kDa band and α-tubulin loading controls, showing increased levels of TSP-2 expression in GTM cells compared to the NTM cells. . (C) (ii) Densitometry analysis of
TSP-2 expression in primary NTMand GTM cells (results shown as fold change relative to NTM cells). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the Web version of this article).)
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3.3. TSP-2 alters the expression of ﬁbronectin levels in TM cells
The eﬀects of either TSP-2 or TSP-1 were investigated upon their
ability to modulate the expression of ﬁbronectin. GTM3 cell line, pri-
mary NTM and GTM cells were treated with exogenous 2 μg/ml TSP-2
or -1 recombinant protein for three days. Whole cell lysates were col-
lected to determine the levels of ﬁbronectin and analysed via western
immuno-blot analysis.
Fibronectin is expressed at the protein level in control untreated
GTM3 cells and primary NTM and GTM cells (Fig. 4 A and B). Fi-
bronectin protein levels were further increased following treatment
with 2 μg/ml TSP-2 peptide for three days in the GTM3 cells, which
showed approximately 2.3 fold increase in ﬁbronectin levels, compared
to the control untreated GTM3 cells, (Fig. 4 A (i) and B (i)). Fibronectin
levels in TSP-1 treated GTM3 cells (0.8 fold) were comparable to con-
trol untreated cells (Fig. 4 A (i) and B (i)).
Primary NTM cells showed a signiﬁcant increase in ﬁbronectin
protein expression following either TSP-2 or -1 treatments, with ap-
proximately 1.6 and 1.7 fold increase, respectively (Fig. 4 A (ii) and B
(ii)). Primary GTM cells also showed approximately 2 and 2.5 fold in-
crease in ﬁbronectin expression with TSP-2 or TSP-1 treatment, re-
spectively (Fig. 4 A (iii) and B (iii)).
Fig. 2. TSP-2 and -1 protein and mRNA expression in glaucomatous human GTM3 cells in response to TGFβ2 and DEX. GTM3 cells were exposed to 2 ng/ml
TGFβ2 or 100 nM DEX for 3 days. TSP-2 protein was measured by immuno-blot analysis. (A) (i) Representative immuno-blot showing levels of TSP-2 protein
expression in GTM3 cells, following treatment with TGFβ2 and DEX. A (ii) Representative immuno-blot showing increased levels of TSP-1 protein expression in
GTM3 cells, following treatment with TGFβ2 and DEX. (B) (i and ii) Histograms of densitometry analysis showing TSP-2 and TSP-1 protein fold increases in GTM3
cells following treatment with TGFβ2 and DEX, relative to untreated control cells. Error bars represent standard deviation, n = 3, p < 0.05. (C) GTM3 cells were
exposed to 2 ng/ml TGFβ2 or 100 nM DEX for 3 days. TSP-2 and TSP-1 mRNA levels were measured using qPCR and mRNA levels normalised to housekeeping gene
(GAPDH). Results shown as fold change compared to control GTM3 untreated cells. (C) (i) Represents TSP-2 and (ii) represents TSP-1 mRNA expressions. Error bars
represent SD (n = 3), * represents p < 0.05 (One way ANOVA and post hoc Tukey's analysis).
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4. Discussion
Thrombospondins are important regulators of ECM interactions and
modulating cellular responses in vivo. TSP-1 levels are elevated in POAG
patients, however less is known about the expression and function of
TSP-2 of which it shares similar structural and sequence homology
(Bornstein, 1995; Bornstein and Sage, 2002). On this basis, we have
investigated if TSP-2 is expressed within the TM in vitro, whether its
levels are increased via TGFβ2 stimulation, and also the downstream
eﬀects of TSP-2 expression upon the ECM. In this study we found that
TSP-2 is expressed by both primary and immortalised TM cells and
protein levels are up-regulated via TGFβ2 treatment. We further de-
monstrated that glaucomatous TM cells (GTM3), primary NTM and
GTM cells can respond to exogenous TSP-2 treatment and are capable of
increasing ﬁbronectin levels at the time point analysed. In contrast,
TSP-1 had no signiﬁcant eﬀect upon the ﬁbronectin levels in GTM3
cells, but in primary NTM and GTM cells ﬁbronectin was increased
following both TSP-1 or TSP-2 treatments. To the best of our knowl-
edge, this is the ﬁrst report which demonstrates that TSP-2 is up-
regulated via TGFβ2 treatment in TM cells and can modulate the ﬁ-
bronectin levels within the ECM environment.
Our data corroborates ﬁndings observed by others of TSP-2 ex-
pression in TM cells and also within TM tissue (Haddadin et al., 2012;
Hiscott et al., 2006). Previous studies have shown that TSP-2 is ex-
pressed predominantly within the uveal meshwork in healthy TM cells,
suggesting that TSP-2 has a role in healthy TM tissue speciﬁc to the
uveal meshwork (Hiscott et al., 2006). In contrast, TSP-1 is expressed
predominantly in the JCT in healthy TM, whereas its distribution is
found throughout the TM in glaucomatous patients (Flugel-Koch et al.,
2004). This diﬀerential localisation between TSP-2 and TSP-1 within
the TM may diﬀerentially regulate the expression of ECM proteins
throughout the diﬀerent regions of the TM in response to ﬂuctuations in
IOP. However, the distribution of TSP-2 in glaucomatous tissue requires
further investigation.
Regulation of the TM ECM is essential for the regulation of normal
IOP. TGFβ2 is present in the aqueous humour under normal conditions
(Granstein et al., 1990) and basal levels of TGFβ2 activation may be
required for the continuous secretion of ECM molecules to regulate the
Fig. 3. TSP-2 and -1 protein and mRNA expression in primary human TM cells in response to TGFβ2 and DEX. Primary TM cells were exposed to 2 ng/ml
TGFβ2 or 100 nM DEX for 3 days. TSP-2 and -1 protein was measured by immuno-blot analysis (A) Representative immuno-blots showing levels of TSP-2 protein
expression in (i) primary NTM cells and (ii) primary GTM cells and TSP-1 expression (iii) in primary NTM cells following treatment with TGFβ2 and DEX. (B)
Histograms of densitometry analysis showing TSP-2 and TSP-1 protein fold increases in primary NTM and GTM cells, following treatment with TGFβ2 and DEX,
relative to untreated control cells. (B) (i) represents TSP-2 expression in primary NTM cells and (ii) in primary GTM cells and TSP-1 expression in (iii) in primary NTM
cells. (C) TSP-2 and TSP-1 mRNA levels were measured using qPCR and mRNA levels normalised to housekeeping gene (GAPDH) in primaryTM cells. Results shown
as fold change compared to control untreated cells. (C) (i) Represents TSP-2 mRNA expression in primary NTM cells, (ii) represents TSP-1 mRNA expression in
primary GTM cells and (iii) represents TSP-1 mRNA expression in primary NTM cells. Error bars represent standard deviation, n = 6 for NTM and n = 3 for GTM.
Symbol * represents signiﬁcantly diﬀerent (p < 0.05) using One way ANOVA and post hoc Tukey's analysis.
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normal turnover by the ECM matrix. It is plausible that TSP-2 may form
part of the normal regulation of the TM ECM environment to control the
AH outﬂow in response to TGFβ2 signalling. Studies have shown that
TGFβ2 increases ECM protein synthesis in cultured TM cells and is an
important mediator of ECM synthesis, secretion and degradation in the
human TM (Fleenor et al., 2005, 2006; Gottanka et al., 2004; Shepard
et al., 2010, Welge-Lussen and Lutjen-Drecoll, 2000). TGFβ2 is involved
in the pathogenesis of glaucoma (Lutjendrecoll et al., 1989; Lutjen-
Drecoll, 2005) and is elevated in the AH of POAG patients (Tripathi
et al., 1994). In our in vitro model, a dose of 2 ng/ml TGFβ2, which
induces glaucomatous eﬀects in TM cells (O'reilly et al., 2011), results
in increases in TSP-2, as well as TSP-1. It is well-documented that TSP-1
is up-regulated via TGFβ1 and -2 in the TM (Flugel-Koch et al., 2004),
however we have shown that TSP-2 is also up-regulated via TGFβ2 in
TM cells.
In contrast with other reports, TSP-2 has not been detected in TM
cell microarray or proteomic analysis performed 24 h post treatment
with TGFβ2, nor did it show an increase at the protein level (Haddadin
et al., 2012; Clark et al., 2013). However, this diﬀerence could poten-
tially be due to the diﬀerences in the duration of TGFβ2 treatments. Our
data suggests that TSP-2 may be secreted at later time points following
TGFβ2 treatment, rather than at 24 h as in previous studies (Haddadin
et al., 2012). It has previously been reported that TSP-1 is only in-
creased in one third of POAG patients (Flugel-Koch et al., 2004). It is
plausible that this might be the case for TSP-2 as well. We observed a
signiﬁcant increase in both TSP-1 and -2 mRNA expression in response
to TGFβ2 in GTM3 cell line. We did not observe signiﬁcant increases in
TSP-2 mRNA primary NTM or GTM cells, despite observing signiﬁcant
increases at the protein level. Interestingly, we did observe increases in
TSP-2 mRNA expression in half of the donors samples tested, whilst
TSP-1 mRNA levels was consistently upregulated in all donors. Whether
this diﬀerence was due to donor variability is unclear and would war-
rant further studies.
We identiﬁed a consistent lower band in immunoblots for both TSP-
2 and TSP-1 in primary NTM and GTM cells around the 70 kDa band.
Abu El-Asrar et al. have also reported TSP-2 as a marker of proliferative
diabetic retinopathy (PDR) (Abu El-Asrar et al., 2013). TSP-2 ran as two
bands with the upper band reportedly correlated with the intact protein
and the lower band as cleaved TSP-2, which was increased in vitreous
samples from PDR patients. They hypothesised that the increased ex-
pression of TSP-2 cleaved product may be due to elevated levels of
MMP-9 in PDR inducing proteolytic clearance of TSP-2. Thus, sug-
gesting that a negative feedback system between MMP-9 and TSP-2
requiring further investigation.
Our ﬁndings showed that the DEX response in the TM cells was
more variable and did not result in signiﬁcant increases in the TSP-1 or
TSP-2 expression in TM cells. Other studies have shown that the TSP-1
response was lower with TGFβ1 (2 fold) at 3 days compared to DEX
(Flugel-Koch et al., 2004). Glucocorticoids are reported to increase the
deposition of ECM material (Acott and Kelley, 2008), in particular the
ﬁbronectin levels (Steely et al., 1992; Filla et al., 2017). Unpublished
data from our laboratory has also shown an increase in ﬁbronectin in
response to DEX, but the extent of the increase was signiﬁcantly lower
to that of TGFβ2. It is therefore possible that DEX treatment on TM cells
increases ﬁbronectin levels via a TSP-1 and TSP-2 independent me-
chanism. Although the eﬀects of DEX upon TM cells can be observed at
3 days (Raghunathan et al., 2015; Jain et al., 2013; Kasetti et al., 2017)
investigating the eﬀects of DEX at longer time points would require
further investigation.
TSP-2 increased the expression of ﬁbronectin in TM cells, suggesting
a possible role for TSP-2 in ECM regulation and hence the pathogenesis
of glaucoma. TGFβ2 increases ﬁbronectin levels in TM cells and aqu-
eous humour (Acott and Kelley, 2008; Faralli et al., 2009; Wordinger
et al., 2007). Fibronectin is a multifactorial ECM glycoprotein and is not
only a major structural component of the ECM, but it also functions as a
signalling molecule itself and regulates AH outﬂow (Acott and Kelley,
2008; Faralli et al., 2009; Keller et al., 2009). Recent data suggests that
disruption of ﬁbronectin ﬁbrillogenesis can prevent the incorporation
of other ECM proteins into the ECM (Filla et al., 2017). It has been
shown that cellular ﬁbronectin, a stretched and insoluble isoform of
ﬁbronectin that is secreted and assembled into dense complex ﬁbril
networks, aﬀecting overall ECM-cell interactions as well as ECM
Fig. 4. Eﬀect of TSP-2 upon the expression of ECM protein ﬁbronectin in TM cells. Immuno-blot and densitometry analysis of GTM3 and primary non glau-
comatous TM (NTM) and glaucomatous TM (GTM) cells treated with either 2 μg/ml TSP-2 or TSP-1 recombinant human protein for 3 days. (A) Shows the im-
munoblot of (i) GTM3 cell line, (ii) primary NTM cells and (iii) primary GTM cells, samples treated with TSP-2 or -1 for 3 days, probed for ﬁbronectin, shown as a
250 kDa band. (B) Densitometry analysis shows fold change in ﬁbronectin protein expression (i) GTM3 cell line, (ii) primary NTM cells and (iii) primary GTM cells.
Bands were normalised to α-tubulin (55 kDa band) and results are shown as fold change compared to untreated control for each cell line. Error bars represent
standard deviation (n = 3 for GTM3 and n = 6 for primary NTM cells and n = 3 for primary GTM cells). Symbol * represents signiﬁcantly diﬀerent (p < 0.05) using
One way ANOVA and post hoc Tukey's analysis.
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homeostasis, is speciﬁcally induced by TGFβ2 (Medina-Ortiz et al.,
2013). It has been proposed that this might be a novel pathologic me-
chanism in the TM changes associated with glaucoma (Medina-Ortiz
et al., 2013). The present study did not distinguish between the cellular
or secreted forms of ﬁbronectin, but the increase in ﬁbronectin levels in
response to TGFβ2 treatment support our hypothesis that TSP-2 may be
involved within this process. In addition, TSP-2 knockout mice de-
monstrated lower IOP levels (Haddadin et al., 2012), which suggests
TSP-2 may regulate the IOP levels, via regulation of the ﬁbronectin
levels, hence suggesting a potential role in the pathogenesis of POAG.
TSP-2 can regulate the levels of MMP-2 by being able to bind and
inactivate MMPs (notably MMP-2) (Bornstein and Sage, 2002;
Bornstein et al., 2000), which are responsible for the degradation of the
ECM environment via its internalisation (Yang et al., 2001). Levels of
MMP-2 are also increased in TSP-2 knockout out mice (Kyriakides et al.,
2001). There are decreased levels of MMP-2 activity in glaucomatous
cells (Schlotzer-Schrehardt et al., 2003) and the levels are further de-
creased in TM cells treated with TGFβ2 and DEX (Fuchshofer et al.,
2003; Snyder et al., 1993), which may be responsible for increasing the
deposition of ECM components, giving rise to impaired outﬂow re-
sistance. MMP-2 levels are also decreased with stretch experiments on
the TM (Vittal et al., 2005) increasing the ﬂow rate, whereas TSP-2
levels were increased with the stiﬀness of the TM. TSP-2 may therefore
also contribute to the mechanical properties of the TM through mod-
ulation of ﬁbronectin levels.
5. Conclusions
In summary, TSP-2 increased the expression of ﬁbronectin in glau-
comatous TM cell line, as well as primary NTM and GTM cells and its
levels were inﬂuenced by TGFβ2. TSP-2 expression within the TM may
therefore be involved in the pathogenesis of POAG and contribute to
increased IOP levels by increasing the deposition of ﬁbronectin within
the ECM. Although the levels of TSP-2 are not likely to be major drivers
of POAG, it does however provide further insight into the potential
mechanisms of ﬁbronectin deposition and up-regulation within the TM
during the pathogenesis of POAG via TGFβ2 signalling. Elucidating the
role of TSP-2 in ECM regulation and of TSP-1 and-2 in the regulation of
cell matrix interactions may provide future targets for regulation of the
ECM in the TM.
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